Cohen M H, Jessup J M, Felix E L, Weese J L, Herberman R B
Cancer. 1978 Jun;41(6):2456-63. doi: 10.1002/1097-0142(197806)41:6<2456::aid-cncr2820410654>3.0.co;2-b.
Eighteen patients with multiple recurrences of malignant melanoma without evident distant spread were randomly assigned to treatment with either intralesional Bacillus Calmette-Guerin (BCG) or intralesional dinitrochlorobenzene (DNCB). Both agents were able to destroy approximately 90% of the injected intradermal nodules. Intradermal disease was more easily obliterated than subcutaneous disease with intralesional treatment with either agent, and local control of satellitosis with elimination of all clinically evident tumor was achieved in the patients who had intradermal without subcutaneous satellitosis, regardless of whether the patient was receiving BCG or DNCB. The clinical courses of the treated patients were essentially the same. Although PHA reactivity was depressed, the patients in both groups were responsive to recall and melanoma skin test antigens, demonstrated leukocyte migration inhibition with melanoma antigen and were generally within normal limits when assayed for 29 degrees C E rosettes. Our study demonstrated a dramatic difference in toxicity between the two intralesional agents without a similar difference in therapeutic efficacy or immune testing.
18例无明显远处转移的恶性黑色素瘤多次复发患者被随机分配接受病灶内注射卡介苗（BCG）或二硝基氯苯（DNCB）治疗。两种药物均能破坏约90%的注射皮内结节。使用任一药物进行病灶内治疗时，皮内病灶比皮下病灶更容易消除，在无皮下卫星灶的皮内病灶患者中，无论患者接受BCG还是DNCB治疗，通过消除所有临床可见肿瘤均实现了卫星灶的局部控制。治疗患者的临床病程基本相同。尽管PHA反应性降低，但两组患者对回忆抗原和黑色素瘤皮肤试验抗原均有反应，对黑色素瘤抗原表现出白细胞迁移抑制，并且在检测29℃E玫瑰花结时通常在正常范围内。我们的研究表明，两种病灶内药物在毒性上存在显著差异，但在治疗效果或免疫检测方面没有类似差异。
